Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Outros |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/124269 |
Resumo: | Funding Information: MM participated in advisory board meetings and received speaker’s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting/speaker’s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly. Publisher Copyright: © 2021, The Author(s). |
id |
RCAP_f749b70f7c89b9e91da129e035ead305 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/124269 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials resultscan definition of established cardiovascular disease be the missing link?Antidiabetic drugCardiovascular diseaseCardiovascular outcome trialsGLP-1 RAType 2 diabetesInternal MedicineEndocrinology, Diabetes and MetabolismSDG 3 - Good Health and Well-beingFunding Information: MM participated in advisory board meetings and received speaker’s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting/speaker’s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly. Publisher Copyright: © 2021, The Author(s).Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce blood glucose levels with a low associated risk of hypoglycaemia. CVOTs with different GLP-1 RAs yielded different results in terms of major cardiovascular composite outcome (MACE), with some trials showing superiority in the treatment arm, whereas other simply displayed non-inferiority. More importantly, the significance of each component of MACE varied between drugs. This begs the question of whether these differences are due to dissimilarities between drugs or other factors, namely trial design, are at the root of these differences. We analyse the trial designs for all CVOTs with GLP-1 RAs and highlight important differences between them, namely in terms of definition of established cardiovascular disease, and discuss how these differences might explain the disparate results of the trials and preclude direct comparisons between them. We conclude that a fair comparison between GLP-1 RA CVOTs would involve post-hoc analysis re-grouping the patients into different cardiovascular risk categories based upon their baseline clinical parameters, in order to even out the criteria used to classify patients.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNMelo, MiguelGavina, CristinaSilva-Nunes, JoséAndrade, LuísCarvalho, Davide2021-09-09T00:27:39Z2021-07-272021-07-27T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttp://hdl.handle.net/10362/124269engPURE: 33428612https://doi.org/10.1186/s13098-021-00698-5info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:55:58Zoai:run.unl.pt:10362/124269Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:55:58Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results can definition of established cardiovascular disease be the missing link? |
title |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results |
spellingShingle |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results Melo, Miguel Antidiabetic drug Cardiovascular disease Cardiovascular outcome trials GLP-1 RA Type 2 diabetes Internal Medicine Endocrinology, Diabetes and Metabolism SDG 3 - Good Health and Well-being |
title_short |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results |
title_full |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results |
title_fullStr |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results |
title_full_unstemmed |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results |
title_sort |
Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results |
author |
Melo, Miguel |
author_facet |
Melo, Miguel Gavina, Cristina Silva-Nunes, José Andrade, Luís Carvalho, Davide |
author_role |
author |
author2 |
Gavina, Cristina Silva-Nunes, José Andrade, Luís Carvalho, Davide |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
dc.contributor.author.fl_str_mv |
Melo, Miguel Gavina, Cristina Silva-Nunes, José Andrade, Luís Carvalho, Davide |
dc.subject.por.fl_str_mv |
Antidiabetic drug Cardiovascular disease Cardiovascular outcome trials GLP-1 RA Type 2 diabetes Internal Medicine Endocrinology, Diabetes and Metabolism SDG 3 - Good Health and Well-being |
topic |
Antidiabetic drug Cardiovascular disease Cardiovascular outcome trials GLP-1 RA Type 2 diabetes Internal Medicine Endocrinology, Diabetes and Metabolism SDG 3 - Good Health and Well-being |
description |
Funding Information: MM participated in advisory board meetings and received speaker’s fees from the following companies: AstraZeneca, Bial, Boeringher-Ingelheim, Lilly, NovoNordisk and Sanofi. CG reports consulting and speaking fees from Astrazeneca, Novo Nordisk, Lilly, Boheringer Ingelheim, MSD and Bayer. JSN reports receiving research funding from AstraZeneca, and Merck sa; and consulting/speaker’s fees from Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Janssen, Lilly, Medinfar, Merck sa, Merck Sharp & Dohme, Mundipharma, Novartis, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede. LA reports membership of advisory board, consultancy/ speaker's fees from: Astra-Zeneca, Lilly, Bhoeringer, NovoNordisk and Bial.DC is member of Advisory Boards of Novo-Nordisk, Astra-Zeneca, Eli Lilly, Sanofi-Aventis and is speaker for Novo-Nordisk, Astra-Zeneca, Eli Lilly. Publisher Copyright: © 2021, The Author(s). |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09-09T00:27:39Z 2021-07-27 2021-07-27T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/other |
format |
other |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/124269 |
url |
http://hdl.handle.net/10362/124269 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
PURE: 33428612 https://doi.org/10.1186/s13098-021-00698-5 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817545820543647744 |